Spots Global Cancer Trial Database for Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Official Title: A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer
Study ID: NCT00147537
Conditions
Study Description
Brief Summary: Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Tucson, Arizona, United States
Pfizer Investigational Site, Tucson, Arizona, United States
Pfizer Investigational Site, Tucson, Arizona, United States
Pfizer Investigational Site, Greenbrae, California, United States
Pfizer Investigational Site, Los Angeles, California, United States
Pfizer Investigational Site, Jacksonville, Florida, United States
Pfizer Investigational Site, Jacksonville, Florida, United States
Pfizer Investigational Site, Jeffersonville, Indiana, United States
Pfizer Investigational Site, Louisville, Kentucky, United States
Pfizer Investigational Site, Louisville, Kentucky, United States
Pfizer Investigational Site, Louisville, Kentucky, United States
Pfizer Investigational Site, Louisville, Kentucky, United States
Pfizer Investigational Site, Shelbyville, Kentucky, United States
Pfizer Investigational Site, Baltimore, Maryland, United States
Pfizer Investigational Site, Rochester, Minnesota, United States
Pfizer Investigational Site, Corinth, Mississippi, United States
Pfizer Investigational Site, Southaven, Mississippi, United States
Pfizer Investigational Site, Creve Coeur, Missouri, United States
Pfizer Investigational Site, St. Louis, Missouri, United States
Pfizer Investigational Site, St. Peters, Missouri, United States
Pfizer Investigational Site, Bronx, New York, United States
Pfizer Investigational Site, Bronx, New York, United States
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Pfizer Investigational Site, Memphis, Tennessee, United States
Pfizer Investigational Site, Memphis, Tennessee, United States
Pfizer Investigational Site, Houston, Texas, United States
Pfizer Investigational Site, Montreal, Quebec, Canada
Pfizer Investigational Site, Orbassano (TO), , Italy
Pfizer Investigational Site, L'hospitalet de Llobregat, Barcelona, Spain
Pfizer Investigational Site, Madrid, , Spain
Pfizer Investigational Site, Sevilla, , Spain
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
